BIOLASE, Inc. (BIOL)

Market Cap	1.92M
Revenue (ttm)	50.81M
Net Income (ttm)	-28.97M
Shares Out	1.04M
EPS (ttm)	-267.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,352
Open	1.71
Previous Close	1.69
Day's Range	1.70 - 1.90
52-Week Range	1.56 - 269.00
Beta	1.28
Analysts	Strong Buy
Price Target	113.33 (+6,059.24%)
Earnings Date	Nov 9, 2023

About BIOL

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; di...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 13, 1992
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOL

Financial Performance

In 2022, BIOLASE's revenue was $48.46 million, an increase of 23.67% compared to the previous year's $39.19 million. Losses were -$28.85 million, 72.7% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for BIOL stock is "Strong Buy." The 12-month stock price forecast is $113.33, which is an increase of 6,059.24% from the latest price.

Price Target

$113.33

(6,059.24% upside)

Analyst Consensus: Strong Buy